 |
|
|
|
|
|
| |
Photo: © 2004 Netherlands Board of Tourism & Conventions
Industry Sponsored Symposia
Saturday, 13 June
 11.45 – 13.00
Industry Sponsored Symposium: MSD
ISY01 Update in glaucoma – new data for the comprehensive
management of the glaucoma patient
| Moderator: |
Clive Migdal, United Kingdom |
Welcome and opening remarks
Clive Migdal, United Kingdom
Decision-making in glaucoma management: the role of the updated EGS Guidelines
Clive Migdal, United Kingdom
New clinical data on visual field outcomes with known glaucoma therapies
Antonio Martinez Garcia, Spain
24-hour IOP management – new clinical data with fixed-dose combination glaucoma
therapies
Anastasios Konstas,Greece
Elevated IOP – medical treatment options
Carroll Webers, The Netherlands
Panel Discussion
Closing Remarks
Clive Migdal, United Kingdom
14.30 – 16.00
Industry Sponsored Symposium: Alcon
ISY02 New therapeutic options in glaucoma and dry eye
| Moderator: |
Carroll Webers, The Netherlands |
Is efficacy the primary factor in glaucoma?
Gianluca Manni, Italy
How does comfort influence treatment compliance?
Garbor Hollo, Hungary
Vascular factor: myths and real facts
Alon Harris, United States
Does the patient profile influence treatment patterns?
Francisco Javier Goñi, Spain
New perspectives in the diagnosis and treatment of dry eye
Jose Maria Benítez del Castillo, Spain
16.30 – 18.00
Industry Sponsored Symposium: Allergan
ISY03 Myths and realities in glaucoma
| Moderators: |
Clive Migdal, United Kingdom |
| |
Anders Heijl, Sweden |
Intro and welcome
Clive Migdal, United Kingdom
Anders Heijl, Sweden
Myths and realities in glaucoma today; do patients go blind?
Anders Heijl, Sweden
Myths and realities in glaucoma; risk factors
Balwantray Chauhan, Canada
Myths and realities of rate of progression
David Crabb, United Kingdom
Myths and realities in management of patients at risk
Francesco Oddone, Italy
Myths and realities of the PEX patient
Anastasios Konstas, Greece
Panel discussion – myths and realities in glaucoma
Moderators and panel
Sunday, 14 June
10.15 – 11.45
Industry Sponsored Symposium: Santen
ISY04 A new direction in topical glaucoma therapy
| Moderator: |
Clive Migdal, United Kingdom |
A dual problem: dry eye and glaucoma
Carl Erb, Germany
Eye drops and ocular surface disease: are we doing our patients a disservice?
David Broadway, United Kingdom
Switching from preserved to preservative free prostaglandins: the clinical
experience
Norbert Pfeiffer, Germany
Profile of a new preservative free prostaglandin
Hannu Uusitalo, Finland
11.45 – 13.00
Industry Sponsored Symposium: Novartis
ISY05 A new era in the treatment of neovascular AMD:
applying latest Lucentis data to advance clinical practice
| Moderator: |
Reinier O. Schlingemann, The Netherlands |
Current perspectives in treatment of neovascular AMD with Lucentis
Building on the evidence: 12-month data from the SUSTAIN trial
Breaking data from the MONT BLANC study in neovascular AMD
Applying trial data to treatment regimens in everyday clinical practice
Panel discussion: how will recent data affect management of neovascular AMD?
Summary & closing remarks
14.30 – 16.00
Industry Sponsored Symposium: MSD
ISY06 A new therapeutic option for the medical management of glaucoma
| Moderator: |
Roger Hitchings, United Kingdom |
Welcome and opening remarks
Roger Hitchings, United Kingdom
Decision-making in glaucoma management: the role of the updated EGS guidelines
Clive Migdal, United Kingdom
Glaucoma, ocular surface disease and the role of preservative-free medications
Christophe Baudouin, France
IOP lowering efficacy and tolerability of Tafluprost
Carlo Traverso, Italy
Tafluprost phase IIIb overview
Hannu Uusitalo, Finland
Panel discussion
Faculty
Closing remarks
Roger Hitchings, United Kingdom
16.30 – 18.00
Industry Sponsored Symposium: Pfizer
ISY07 Monitoring and managing glaucoma progression: the great debate
| Moderator: |
Norbert Pfeiffer, Germany |
Monitoring the progressing patient: what are the challenges?
Thierry Zeyen, Belgium
Clinical progression: what structural changes can be observed?
Fotis Topouzis, Greece
Imaging technology: are current advances improving clinical evaluation?
David Garway-Heath, United Kingdom
Progression under the microscope: can basic science provide the link between
structural and functional deterioration?
Keith Martin, United Kingdom
Tailoring therapy for the progressing patient: what is the best approach?
Norbert Pfeiffer, Germany
Monday, 15 June
11.45 – 13.00
Industry Sponsored Symposium: Allergan
ISY08 The role of inflammation in macular edema
| Moderators: |
Anat Loewenstein, Israel |
| |
Mark Blumenkrantz, United States |
Introduction
Anat Loewenstein, Israel
Mark Blumenkrantz, United States
Macular edema: evidence for inflammation
Mark Blumenkrantz, United States
Steroids and management of macular edema
Baruch Kuppermann, United States
New developments in macular edema
Anat Loewenstein, Israel
Combination treatment in macular edema – a clinical update
Albert Augustin, Germany
Management of macular edema – today and tomorrow
Panel discussion – patient cases
Anat Loewenstein, Israel
Baruch Kuppermann, United States
Mark Blumenkrantz, United States
Albert Augustin, Germany
Scott Whitcup, United States
Sum up
Anat Loewenstein, Israel
Mark Blumenkrantz, United States
|
|
|
|
|
|
|
|
|
|
